

RECEIVED  
 TECH CENTER 1600  
 MAY 16 2002

LIST OF ART CITED BY APPLICANT  
 (PTO-1449)



ATTY. DOCKET NO.  
 Old: 114205.2402  
 New:  
 215101.02402

APPLICANT  
 William G. KERR.

FILING DATE  
 September 19, 2001

GROUP  
 1614

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
03	6,090,621	18 Jul 2000	Kavanaugh et al.			
03	4,603,112	29 Jul 1986	Paoletti et al.			
	4,769,330	6 Sep 1988	Paoletti et al.			
	5,017,487	21 May 1991	Stunnenberg et al.			
	4,777,127	11 Oct 1988	Suni et al.			
	5,166,057	24 Nov 1992	Palese et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation Yes	No
03	WO 97/10252A1	13 Sep 1996	Rohrschneider, L.R.				
03	WO 97/12039A2	27 Sep 1996	Krystal, G.				
	WO 89/01973	9 Mar 1989	Panicali, D. et al.				
	GB 2,200,651	14 Sep 1988	Al-Sumidaie, A.M.K.				
	EP 0,345,242	6 Dec 1989	Jacobs, E. et al.				
	WO 91/02805	7 Mar 1991	Chang, S.M.W. et al.				
	EP 0 440,219	7 Aug 1991	Billeter, M.A. et al.				
	WO 92/06693	30 Apr 1992	Taylor, J.D.				

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

Kapeller et al., "Phosphatidylinositol 3-Kinase," *Bioessays*, 16, 1994: 565-76.

Stephens, L.R. et al., "Agonist-stimulated synthesis of phosphatidylinositol(3,4,5)-trisphosphate: a new intracellular signalling system?" *Biochim. Biophys Acta*, 1179, 1993: 27-75.

Hawkins P.T. et al., "Platelet-derived growth factor stimulates synthesis of PtIns(3,4,5)P<sub>3</sub> by activating a PtIns(4,5)P<sub>2</sub> 3-OH kinase," *Nature*, 358, 1992: 157-910.

Kipper A. et al., "Membrane localization of phosphatidylinositol 3-kinase is sufficient to activate multiple signal-transducing kinase pathways," *Molecular and Cellular Biology*, vol. 16, no. 8, 1996: 4117-27.

Helgason, C.D. et al., "Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span," *Genes & Dev.*, vol. 12, no. 11, 1998: 1610-20.

Huber, M. et al., "The src homology 2-containing inositol phosphatase (SHIP) is the gatekeeper of mast cell degranulation," *Proc. Natl. Acad. Sci. U.S.A.*, vol. 95, no. 19, 1998: 11330-35.

Liu, Q. et al., "SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell survival," *Genes & Dev.*, vol. 13, no. 7, 1999: 789-91.

Liu, Q. et al., "The inositol polyphosphate 5-phosphatase SHIP is a crucial negative regulator of B cell antigen receptor signalling," *J. Exp. Med.*, vol. 188, no. 7, 1998: 1333-42.

RECEIVED  
 MAY 16 2002  
 TECH CENTER 1600/2900

OTHER ART (including Author, Title, Date, Pertinent Pages, Etc.)	
82	Jefferson, A.B. et al. "Properties of type II inositol polyphosphate 5-phosphatase;" J. Biol. Chem. vol. 270, no. 16, 1995: 9370-77.
13 2002	Wang, C.Y. et al., "pH-sensitive immunoliposomes mediate target-cell-specific delivery and controlled expression of a foreign gene in mouse;" PNAS, vol. 84, 1987: 7851.
TRADEMA	Jolly, D., "Viral vector systems for gene therapy," Cancer Gene Therapy, vol. 1, no. 1, 1994: 51-64.
	Evans, D.J. et al., "An engineered poxvirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies;" Nature, vol. 339, 1989: 385-88.
	Sabin, A.B. et al., "History of Sabin attenuated poliovirus oral live vaccine strains;" J. of Biol. Standardization, vol. 1, 1973: 115-18.
	Fisher-Hoch, S.P. et al., "Protection of rhesus monkeys from fatal Lassa fever by vaccination with recombinant vaccinia virus containing the Lassa virus glycoprotein gene;" PNAS, vol. 86, 1989: 317-21.
	Moss, B. et al., "Vaccinia virus expression vectors;" Ann. N.Y. Acad. Sci. vol. 569, 1989: 86-103.
	Flexner, C. et al., "Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2;" Vaccine, vol. 8, 1990: 17-21.
	Mulligan, R.C. et al., "Synthesis of rabbit $\beta$ -globin in cultured monkey kidney cells following infection with a SV40 $\beta$ -globin recombinant genome;" Nature, vol. 277, 1979: 108-114.
	Luytjes, W. et al., "Amplification, expression, and packaging of a foreign gene by influenza virus;" Cell, vol. 59, 1989: 1107-13.
	McMichael, A.J. et al., "Cytotoxic T-cell immunity to influenza;" N. Eng. J. Med., vol. 309, no. 1, 1983: 13-17.
	Yap, K.L. et al., "Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus;" Nature, vol. 273, 1978: 238-39.
	Berkner, K.L., "Development of adenovirus vectors for the expression of heterologous genes;" BioTechniques, vol. 6, no. 7, 1988: 616-27.
	Rosenfeld, M.A. et al., "Adenovirus-mediated transfer of a recombinant $\alpha 1$ -antitrypsin gene to the lung epithelium in vivo;" Science, vol. 252, 1991: 431-34.
	Kolis, J. et al., "Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer;" PNAS, vol. 91, 1994: 215-19.
	Kass-Eisler, A. et al., "Quantitative determination of adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and in vivo;" PNAS, 90, 1993:11498-502.
	Guzman, R.J. et al., "Efficient and selective adenovirus-mediated gene transfer into vascular neointima;" Circulation, vol. 88, no. 6, 1993:2838-48.
	Guzman, R.J. et al., "Efficient gene transfer into myocardium by direct injection of adenovirus vectors;" Cir. Res. vol. 73, no. 6, 1993: 1202-07.
	Zabner, J. et al., "Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis;" Cell, vol. 75, 1993: 207-16.
	Li, Q. et al., "Assessment of recombinant adenoviral vectors for hepatic gene therapy;" Hum. Gene Ther., vol. 4, 1993: 403-09.
	Caillaud, C. et al., "Adenoviral vector as a gene delivery system into cultured rat neuronal and glial cells;" Eur. J. Neurosci., vol. 5, 1993: 1287-91.
	Vincent, N. et al., "Long-term correction of mouse dystrophic degeneration by adenovirus-mediated transfer of a minidystrophin gene;" Nat. Genet., vol. 5, 1993: 130-34.
	Jaffé, H.A. et al., "Adenovirus-mediated in vivo gene transfer and expression in normal rat liver;" Nat. Genet., Vol. 1, 1992: 372-78.
	Leviero, M. et al., "Defective and nondefective adenovirus vectors for expressing foreign genes in vitro and in vivo;" Gene, vol. 101, 1991: 195-202.
	Samulski, R.J. et al., "Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression;" J. Vir. vol. 63, No. 9, 1989: 3822-3828.
	Mendelson, E. et al., "Expression and rescue of a nonselected marker from an integrated AAV vector;" Virol., Vol. 166, 1988: 154-65.

MAY 16 2002

RECEIVED

TECH CENTER 1600/2900

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)	
1 P C MAY 13 2002 PATENT & TRADEMARK OFFICE	Kit, S., "Recombinant-derived modified-live herpesvirus vaccines," <i>Immunobiology of Proteins and Peptides V: Vaccines: Mechanisms, Design, and Applications</i> , Atassi, M.Z., Ed. Plenum Press, New York, 215, 1989: 219-36.
	Poznansky, M. et al., "Gene transfer into human lymphocytes by a defective human immunodeficiency virus type 1 vector," <i>J. Virol.</i> , vol. 65, no. 1, 1991: 532-36.
	Munroe, S.S. et al., "Subgenomic RNA sequence of human astrovirus supports classification of astroviridae as a new family," <i>J. Vir.</i> Vol. 67, no. 6, 1993: 3611-14.
	Overbaugh, J. et al., "Molecular cloning of a feline leukemia virus that induces fatal immunodeficiency disease in cats," <i>Science</i> , vol. 239, 1988: 906-10.
	Bender, M.A. et al., "Description and Targeted deletion of 5' hypersensitive site 5 and 6 of the mouse $\beta$ -globin locus control region," <i>Blood</i> , 92, 1998:4394-403.
	Lanier, L.L., "NK cell receptors," <i>Annual Review of Immunology</i> , vol. 16, 1998: 359-93.
	Yokoyama, W.M., "Natural killer cell receptors," <i>Current Opinion in Immunology</i> , vol. 10, no. 3, 1998: 298-305.
	Koh, C. et al., "Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo," <i>Blood</i> , vol. 97, no. 10, 2001: 3132-37.
	Ruggeri, L., "Role of Natural Killer Cell Alloreactivity In HLA-Mismatched Hematopoietic Stem Cell Transplantation," <i>Blood</i> , vol. 94, no. 1, 1999: 333-39.
EXAMINER	DATE CONSIDERED 12/7/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.  
DC #4122404v1-114205.2402/15101.02402

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

**Complete If Known**

Application Number	09/955,174
Filing Date	September 19, 2001
First Named Inventor	William G. Kerr
Art Unit	1635
Examiner Name	Jane J. Zara

Sheet

1

of

1

Attorney Docket Number

USF-T150CX

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
J 3	U1	US-10/605,452	09-30-2003	Kerr et al. (patent application)	All
J 10	U2	US-10/709,801	05-28-2004	Desponts et al. (patent application)	All
	U3	US-10/904,667	11-22-2004	Kerr et al. (patent application)	All
	U4	US-2002/0165192 A1	11-07-2002	Kerr et al.	All
	U5	US-			
	U6	US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	F1				
	F2				
	F3				
	F4				

Examiner Signature

Date Considered

12-7-05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



RECEIVED  
FEB 07 2003  
U. S. PATENT & TRADEMARK OFFICE  
SEARCH CENTER

Approved for use through 10/31/2002 GSA GEN-01  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
OMB Control Number 2001-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

### Complete if Known

Application Number	09/955,174
Filing Date	September 19, 2001
First Named Inventor	William G. Kerr
Art Unit	1614 / 1635
Examiner Name	(not yet assigned)

Attorney Docket Number USF-T150CX

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
SJ	U1	US-6,025,198	12-15-2000	Bennet et al.	throughout
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			
	U10	US-			
	U11	US-			
	U12	US-			
	U13	US-			
	U14	US-			
	U15	US-			
	U16	US-			
	U17	US-			
	U18	US-			
	U19	US-			
	U20	US-			

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)			
	F1				
	F2				
	F3				
	F4				
	F5				
	F6				
	F7				
	F8				
	F9				
	F10				

Examiner Signature

Date Considered

12-8-05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



FEB 07 2003

TECH CENTER 1600/2900

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 14498/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

### Complete If Known

Application Number	09/955,174
Filing Date	September 19, 2001
First Named Inventor	William G. Kerr
Group Art Unit	1614
Examiner Name	(not yet assigned)
Attorney Docket Number	USF-T150CX

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JZ	R1	AKAGI, KIWAMU et al., Cre-mediated somatic site-specific recombination in mice, Nucleic Acids Research, 1997, 25(9):1768-1773. Oxford University Press.	
	R2	LOTZOVA, E. et al., Prevention of Rejection of Allogeneic Bone Marrow Transplants by NK-1.1 Anti Serum, Transplantation, 1983, 35(5):490-494.	
	R3	HELD, WERNER et al., Transgenic expression of the Ly49A natural killer cell receptor confers class I major histocompatibility complex (MHC)-specific inhibition and prevents bone marrow allograft rejection, Journal of Experimental Medicine, 1996 184(5):2037-2041.	
	R4	GHANSAH, TOMAR et al., The Src homology 2 containing inositol phosphatase is vital for the function and homeostasis of Natural Killer cells, FASEB Journal, March 7, 2001, 15(4):A655.	
	R5	KERR, WILLIAM G. et al., Critical Role for SHIP in engraftment of histo-incompatible stem cells, Oncology Research, 2001, 12:285.	
	R6	GHANSAH, TOMAR et al., A role for the SH2-containing inositol phosphatase in the biology of natural killer cells and stem cells, Activating and Inhibitory Immunoglobulin-like Receptors, 2001, 129-140.	
	R7	WANG, JIA WANG et al., Influence of ZSHIP on the NK Repertoire and Allogeneic Bone Marrow Transplantation, Science, 295(5562):2094-2097.	
	R8	DESPONTS, CAROLINE et al., MHC class I inhibitory receptors on natural killer cells recruit SHIP in an attempt to control cell survival, FASEB Journal, March 20, 2002, 16(4):A706.	
↓	R9	GHANSAH, TOMAR et al., Target disruption of Src homology 2-containing 5' inositol phosphatase (SHIP) alters PI3K/AKT and MAPK signal transduction pathways in murine natural killer cells, FASEB Journal, March 20, 2002, 16(4):A706	
	R10		
	R11		
	R12		
	R13		

Examiner Signature		Date Considered	12/5/05
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

2

**Complete if Known:**

Application Number	09/955,174
Filing Date	September 19, 2001
First Named Inventor	William G. Kerr
Art Unit	1635
Examiner Name	Jane J. Zara

Attorney Docket Number

USF-T150CX

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-			
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
QJ	F1	WO 99/32619 A1	07-01-1999	Firer et al.	All	
QJ	F2					
QJ	F3					
QJ	F4					
QJ	F5					
QJ	F6					
QJ	F7					

Examiner Signature


Date Considered

12-8-05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English-language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-788-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

2

**Complete if Known**

Application Number	09/955,174
Filing Date	September 19, 2001
First Named Inventor	William G. Kerr
Group Art Unit	1635
Examiner Name	Jane J. Zara
Attorney Docket Number	USF-T150CX

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.*	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
3	R1	BONETTA, L. "RNAi: Silencing never sounded better" <i>Nature Methods</i> , 2004, 1(1):79-86.	
3	R2	CAPLEN, N.J. et al. "Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems" <i>PNAS</i> , 2001, 98(17):9742-9747.	
	R3	ELBASHIR, S. et al. "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells" <i>Nature</i> , 2001, 411:494-498.	
	R4	ELBASHIR, S. et al. "RNA interference is mediated by 21- and 22-nucleotide RNAs" <i>Genes &amp; Development</i> , 2001, 15:188-200.	
	R5	HARBORTH, J. et al. "Identification of essential genes in cultured mammalian cells using small interfering RNAs" <i>J. Cell Sci.</i> Dec. 2001, 114(PL 24):4557-4565.	
	R6	MONTGOMERY, M.K. et al. "RNA as a target of double-stranded RNA-mediated genetic interference in <i>Ceenorhabditis elegans</i> " <i>Proc. Natl. Acad. Sci. USA</i> , 1998, 95:15502-15507.	
	R7	TUSCHL, T. et al. "RNA interference and small interfering RNAs" <i>ChemBioChem</i> , 2001, 2(4):239-245.	
	R8	TUSCHL, T. et al. "Targeted mRNA degradation by double-stranded RNA in vitro" <i>Genes &amp; Development</i> , 1999, 13:3191-3197.	
	R9	SVOBODA, P. et al. "Selective reduction of dormant maternal mRNAs in mouse oocytes by RNA interference" <i>Development</i> , 2000, 127:4147-4156.	
	R10	ZAMORE, P. et al. "RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals" <i>Cell</i> , 2000, 101:25-33.	
	R11	Office Action mailed 08/29/2005 in continuation-in-part U.S. Serial No. 10/097,101, filed March 14, 2002.	
	R12	Office Action mailed 08/09/2005 in U.S. Serial No. 10/605,452, filed September 30, 2003.	
	R13		

Examiner  
SignatureDate  
Considered

12/8/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Applicant's unique citation designation number (optional). \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.96. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-788-9199) and select option 2.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

### Complete If Known

Application Number	09/955,174
Filing Date	September 19, 2001
First Named Inventor	William G. Kerr
Art Unit	1635
Examiner Name	Jane J. Zara

Sheet

1

of

2

Attorney Docket Number

USF-T150CX

### U.S. PATENT DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>2</sup>	Document Number Number - Kind Code <sup>3</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
QJ	U1	US-6,703,215	03-09-2004	Emeux et al.	All
QJ	U2	US-2004/0072298	04-15-2004	Sauvageau et al.	All
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			

### FOREIGN PATENT DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>2</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)			
	F1				
	F2				
	F3				
	F4				
	F5				
	F6				
	F7				

Examiner Signature

Date Considered

12/8/05

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>4</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/088 (08-03)

Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

2

**Complete If Known**

Application Number	09/955,174
Filing Date	September 19, 2001
First Named Inventor	William G. Kerr
Group Art Unit	1635
Examiner Name	Jane J. Zara

Attorney Docket Number: USF-T150CX

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	-2-
DJ	R1	AGRAWAL, S. "Antisense oligonucleotides: towards clinical trials" <i>TIBTECH</i> , 1996, 14:376-387.	
GC	R2	BRAASCH, D.A. and COREY, D.R. "Novel antisense and peptide nucleic acid strategies for controlling gene expression" <i>Biochemistry</i> , 2002, 41(14):4503-4510.	
	R3	GEWIRTZ, A.M. et al. "Facilitating oligonucleotide delivery: Helping antisense deliver on its promise" <i>Proc. Natl. Acad. Sci. USA</i> , 1996, 93:3161-3163.	
	R4	HELGASON, C.D. et al. "Homeostasis and regeneration of the hematopoietic stem cell pool are altered in SHIP-deficient mice" <i>Blood</i> , 2003, 102:3541-3547.	
	R5	JEN, K-Y and GEWIRTZ, A.M. "Suppression of gene expression by targeted disruption of messenger RNA: Available options and current strategies" <i>Stem Cells</i> , 2000, 18:307-319.	
	R6	LIU, L. et al. "The Src homology 2 (SH2) domain of SH2-containing inositol phosphatase (SHIP) is essential for tyrosine phosphorylation of SHIP, its association with Shc, and its induction of apoptosis" <i>J. Biol. Chem.</i> , 1997, 272:8983-8988.	
	R7	MOODY, J.L. et al. "Anemia, thrombocytopenia, leukocytosis, extramedullary hematopoiesis, and impaired progenitor function in Pten <sup>-/-</sup> mice: a novel model of myelodysplasia" <i>Blood</i> , 2004, 103:4503-4510.	
	R8	OKADA, H. et al. "Cutting edge: Role of the inositol phosphatase SHIP in B cell receptor-induced Ca <sup>2+</sup> oscillatory response" <i>J. Immunol.</i> , 1998, 161:5192-5192.	
	R9		
	R10		
	R11		
	R12		
	R13		

Examiner Signature		Date Considered	12/8/05
--------------------	--	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)  
Approved for use through 07/31/2008. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  
**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

**Complete if Known**

Application Number	09/955,174
Filing Date	September 19, 2001
First Named Inventor	William G. Kerr
Group Art Unit	1635
Examiner Name	Jane J. Zara
Attorney Docket Number	USF-T150CX

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SJ	R1	CANTLEY, L.C. et al. "Oncogenes and signal transduction" Cell, 1991, 64:281-302.	
	R2		
	R3		
	R4		
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		

Examiner Signature	SJ	Date Considered	12/8/05
--------------------	----	-----------------	---------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Applicant's unique citation designation number (optional). <sup>3</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.